From September 15th PR. "The Company has been inf
Post# of 72440
"The Company has been informed by the RBL that it is nearing completion of its in vitro testing of Brilacidin against SARS-CoV-2 and will be submitting findings for peer-review publication. The publication will be solely focused on Brilacidin, with a pre-print made available."
Remdesivir was mentioned 22 times. Must be a good reason. I didn't expect to see R mentioned once.